Vol. 2 No. 8 (2022)
Reimbursement Reviews

Ripretinib (Qinlock)

Published August 25, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Ripretinib (Qinlock), tablets, 50 mg, oral.
  • Indication: For the treatment of adult patients with advanced gastrointestinal stromal tumour who have received prior treatment with imatinib, sunitinib, and regorafenib.